Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 2
1984 2
1985 1
1986 1
1987 1
1988 3
1989 2
1991 2
1992 2
1993 1
1994 3
1995 5
1996 1
1997 2
1998 3
1999 3
2000 4
2001 3
2002 1
2003 5
2004 4
2005 3
2006 5
2007 4
2008 5
2009 3
2010 3
2011 5
2012 2
2013 4
2014 4
2015 3
2016 3
2017 4
2018 4
2019 5
2020 4
2021 3
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Melanoma and Vitiligo: In Good Company.
Failla CM, Carbone ML, Fortes C, Pagnanelli G, D'Atri S. Failla CM, et al. Among authors: d atri s. Int J Mol Sci. 2019 Nov 15;20(22):5731. doi: 10.3390/ijms20225731. Int J Mol Sci. 2019. PMID: 31731645 Free PMC article. Review.
Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma.
Tosi A, Nardinocchi L, Carbone ML, Capriotti L, Pagani E, Mastroeni S, Fortes C, Scopelliti F, Cattani C, Passarelli F, Rosato A, D'Atri S, Failla CM, Cavani A. Tosi A, et al. Among authors: d atri s. Biomedicines. 2021 Dec 16;9(12):1930. doi: 10.3390/biomedicines9121930. Biomedicines. 2021. PMID: 34944746 Free PMC article.
Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Fragale A, Stellacci E, Romagnoli G, Licursi V, Parlato S, Canini I, Remedi G, Buoncervello M, Matarrese P, Pedace L, Ascione B, Pizzi S, Tartaglia M, D'Atri S, Presutti C, Capone I, Gabriele L. Fragale A, et al. Among authors: d atri s. Int J Cancer. 2023 Sep 1;153(5):1080-1095. doi: 10.1002/ijc.34602. Epub 2023 Jun 9. Int J Cancer. 2023. PMID: 37293858
Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
Pallocca M, Molineris I, Berrino E, Marcozzi B, Betti M, Levati L, D'Atri S, Menin C, Madonna G, Ghiorzo P, Bulgarelli J, Ferraresi V, Venesio T, Rodolfo M, Rivoltini L, Lanfrancone L, Ascierto PA, Mazzarella L, Pelicci PG, De Maria R, Ciliberto G, Medico E, Russo G. Pallocca M, et al. Among authors: d atri s. J Transl Med. 2024 Jan 6;22(1):29. doi: 10.1186/s12967-023-04776-2. J Transl Med. 2024. PMID: 38184610 Free PMC article.
Loss of miR-204 expression is a key event in melanoma.
Galasso M, Morrison C, Minotti L, Corrà F, Zerbinati C, Agnoletto C, Baldassari F, Fassan M, Bartolazzi A, Vecchione A, Nuovo GJ, Di Leva G, D'Atri S, Alvino E, Previati M, Nickoloff BJ, Croce CM, Volinia S. Galasso M, et al. Among authors: d atri s. Mol Cancer. 2018 Mar 9;17(1):71. doi: 10.1186/s12943-018-0819-8. Mol Cancer. 2018. PMID: 29523154 Free PMC article.
112 results